Amicus Therapeutics New Jersey – An Intro.

Amicus Therapeutics, a global biotechnology company at the front of all therapies for rare or orphan diseases, has a varied set of platform technologies with medicines in development for those living with rare, devastating diseases, such as the Lysosomal Storage Disorders Fabry disease or the Pompe disease, as well as genetic connective skin disorders like Epidermolysis Bullosa – or EB. The needs of patients within the rare disease community lie at the center of all inventive science, Amicus’s commercial organization, and its diversified clinical programs. Amicus’s goal – stated throughout all levels of each branch – is to make meaningful differences in the lives of all patients and their caregivers.

More information about Amicus Therapeutics and its career opportunities may be found at www.amicusrx.com. Amicus is pleased to submit its new Japanese drug application for its oral precision medicines to combat Fabry disease in Japan. Japan’s a key part of its patient-focused vision in providing migalastat to amenable Fabry patients all over the world – as quickly as possible.

Amicus congratulated Chip Baird for receiving the NJ Tech Council Caren Franzini Hall of Fame Award. Baird’s multiple career achievements have thus elevated him to such recognition among his peers. Team Amicus Therapeutics (:Small Biotech Seems To Have The ‘Big Mo’) also spent three days volunteering through Habitat for Humanity’s Monmouth County – HFHMC – division, serving North East and Western Monmouth County within New Jersey. HFHMC sides with communities to develop decent, affordable housing anyone can live and raise a family.

Amicus Therapeutics was also pleased to share positive data from its newest Pompe Phase 1/2 clinical study, which showed a significant step forward in its mission to develop improved treatment options for those living with Pompe disease. Listen to its live conference calls at 8:30am ET to find out more, or access any replay and slide presentations on the website. Amicus likewise shared its first-quarter 2017 financial results and discussed its 2017 key strategic priorities, including an international launching of its precision medicine to combat Fabry disease, advancements of its Pompe disease with Epidermolysis Bullosa clinical programs, and additional corporate updates. The Webcast and replay were available online.

 
Learn more about Amicus Therapeutics https://finance.yahoo.com/quote/FOLD?ltr=1

Lifeline Screening Seeks to Add More Life to Your Living!

Have you ever wanted to add more life to your years without giving up something that you really enjoy like good food and fellowship? Did you wish there was a tool that helped you see health wise where you can improve your quality of life without giving up your quantity of life? This new innovative approach called Lifeline Screening is designed to give you just that effectively preempting your health in on some of the major causes of sickness today in this world.

Lifeline screening is one of the largest of the world of its kind. It is aimed primarily at vascular screenings and diseases associated with vascular disorders too. It uses a risk formula that is patterned to detect a person’s suitability for the screening process. Lifeline screening seeks to personalize the experience of testing by taking into account a person health history and past indicators of disease trends. It detects these by using a trained team of board certified physicians, supervised by Dr. Manganaro, who looks at the ultrasounds and gives his stamp of quality assurance before the results get any further down in the process. Lifeline screening offers non-invasive ultrasounds and screenings and are always looking to develop new tests and screenings.

Dr.Maganaro has spent his life career devoted to clinical medicine and enjoys informing patients ahead of time of serious life ending conditions like heart disease. Life Screening, he believes, provides infinite possibilities concerning the prevention and detection of cardiovascular diseases in people who initially show no symptoms at all.

http://www.ceocfointerviews.com/interviews/LifeLineScreening17.htm